Advertisement
News
Advertisement

Nuclea raises $5M in first Series C round

Thu, 08/02/2012 - 12:00am
Mass High Tech: The Journal of New England Technology

Nuclea Biotechnologies Inc., which is developing tests for various kinds of cancers as well as diabetes, has closed its first Series C funding round of $5 million to support clinical trials and new hires related to the development of its fatty acid synthase tests for prostate and breast cancers.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading